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Acetobacter 
indonesiensis 
Pneumonia after 
Lung Transplant
To the Editor: Unusual and 
multiresistant bacterial infections are 
increasingly reported in cystic ﬁ  bro-
sis (CF) patients (1). On January 25, 
2007, a 31-year-old man with CF (mu-
tation ΔF 508 and I 507) was admitted 
to our institution in Marseille, France, 
for lung transplantation. His immuno-
suppressive regimen included IV cy-
closporin A (for the ﬁ  rst 6 days with 
conversion to oral tacrolimus thereaf-
ter), azathioprine, and corticosteroids. 
Induction therapy that used antithy-
mocyte globulin was administered 
for the ﬁ  rst 3 days (Thymoglobuline, 
Genzyme Corporation, Naarden, the 
Netherlands). Since 2003, the patient 
was chronically colonized by methi-
cillin-resistant Staphylococcus aureus 
(MRSA),  Pseudomonas aeruginosa 
(susceptible only to colistin  sulfo-
methate), and Candida albicans. Pre-
emptive treatment with antimicrobial 
agents including colistin sulfomethate, 
tobramycin sulfate, ceftazidime, and 
linezolid was administered, starting 
on posttransplant day 1; prophylactic 
caspofungin, followed by inhaled am-
photericin B, was given for the ﬁ  rst 
month. Six and 9 days, respectively, 
after surgery, sputa from the patient 
showed P. aeruginosa and MRSA. 
On postoperative day 11, the pa-
tient’s clinical condition worsened. 
Leukocytes increased to 13.84 × 
109/L. In addition to P. aeruginosa 
(104 CFU/mL) and MRSA (103 CFU/
mL), culture of later sputum samples 
yielded the growth of 104 CFU/mL 
of gram-negative, catalase-positive, 
and oxidase-negative bacillus (isolate 
7120034) on CEPACIA agar (AES, 
Combourg, France) after 72 hours of 
incubation at 30°C. API 20NE, API 
20E, and VITEK 2 Auto system (bio-
Mérieux, Marcy l’Etoile, France) did 
not identify the bacillus. This bacteri-
um was multiresistant to antimicrobial 
agents, including colistin, and was sus-
ceptible only to imipenem, rifampin, 
and aminoglycosides. The ﬁ  nal iden-
tiﬁ  cation of this isolate as Acetobacter 
indonesiensis was achieved after par-
tial sequencing of 16S rRNA gene, as 
previously described (2) (GenBank 
accession no. AJ199841, 99% similar-
ity). The sequence of our isolate has 
been deposited in GenBank under the 
accession no. EF681860. The phylo-
genetic position of isolate 7120034 
among other gram-negative bacteria is 
shown in the Figure. 
Tobramycin was stopped at day 
11, colistin and ceftazidime were 
stopped at postoperative day 14, lin-
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Figure. Phylogenetic tree showing the position of Acetobacter indonesiensis (isolate 
7120034, GenBank accession no. EF681860), in boldface, within acetic acid bacteria and 
other gram-negative rods. The tree was based on 16S rDNA comparison by the neighbor-
joining method. Numbers along the branches indicate bootstrap values.LETTERS
ezolid was maintained for 10 addition-
al days, and gentamicin (for 13 days) 
was added to the patient’s drug thera-
py on February 10. Despite this treat-
ment,  A. indonesiensis was cultured 
from sputa obtained on February 16 
(104 CFU/mL) and February 20 (102 
CFU/mL), respectively. Six days later, 
leukocytes decreased to 8.62 × 109/L, 
and the patient’s condition improved. 
He was discharged at the beginning 
of March. During 7 months of follow-
up, the A. indonesiensis strain was not 
found again.
Acetic  acid bacteria are gram-
negative bacilli classiﬁ  ed into the gen-
era Acetobacter, Gluconobacter, Glu-
conacetobacter, Acidomonas, and the 
recently described genus Asaia; these 
bacteria belong to the α subgroup of 
Proteobacteria ( 3). Isolates of this 
family are recognized as food-asso-
ciated bacteria and are able to grow 
at acidic pH (4). Three species have 
been reported as emerging pathogens 
in humans: Asaia bogorensis (in a case 
of peritonitis in a patient with a peri-
toneal dialysis catheter [5]);  Granu-
libacter bethesdensis (in 3 cases of 
lymphadenitis associated with chronic 
granulomatous disease [6]); and Ac-
etobacter cibinongensis (a recent case 
of bacteremia in a patient receiving 
chronic hemodialysis for end-stage re-
nal failure [7]).
A. indonesiensis has been isolated 
from fruits and ﬂ  owers in Indonesia 
(8); only 3 reports on it have been 
published (3,8,9). In our patient, we 
believe that this multidrug-resistant 
bacterium was the primary cause of 
the infection because the patient was 
eventually cured after an adapted an-
timicrobial drug therapy. Because 
this bacterium grows easily at acidic 
pH (4), a classic condition in the CF 
airway surface liquid, acidity might 
contribute to bacterial adhesion and 
colonization (10). Because acetic acid 
bacteria have never been isolated from 
human  ﬂ  ora, the source of the con-
tamination for our patient remains un-
known.
We also report the antimicrobial 
drug susceptibility of this bacterium. 
It was multiresistant, especially to 
colistin. Antimicrobial drug suscepti-
bility results were obtained by using 
Vitek 2 Auto system because of the 
absence of growth on Mueller-Hinton 
agar. This pattern was also the case for 
G. bethesdensis ( 6). The antimicro-
bial susceptibility of A. cibinongensis 
could not be validated because of the 
lack of interassay reproducibility (7). 
Initial antimicrobial drug therapy for 
this patient with amoxicillin, pristi-
namycin, and cefazolin did not cure 
the patient; he was eventually cured 
after the therapy was switched to to-
bramycin (7).
Our  ﬁ   ndings reemphasize the 
emergence of new colistin-resistant 
pathogens in CF patients, as recently 
reported for Inquilinus limosus ( 1). 
The increased clinical use of nebu-
lized colistin for P. aeruginosa infec-
tion in CF patients may select speciﬁ  c 
colistin-resistant bacteria in such pop-
ulations. In summary, this report of a 
respiratory tract infection caused by 
A. indonesiensis after lung transplan-
tation in a French CF patient supports 
that this multidrug-resistant bacterium 
may be an emerging opportunistic 
pathogen in immunocompromized 
patients, including CF patients with a 
lung transplant.
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